Eevia Health Plc has collaborated with a major international ingredient house over the last 12 months on possible commercial cooperation for the global sales of one of Eevia's ingredients. Following a successful feasibility study conducted by the international partner confirming the ingredient's safety, the project is now progressing to the next stage involving clinical trials, rebranding, and eventual worldwide commercial rollout. During the last 12 months, the ingredient house has conducted various feasibility investigations for a global launch of a new branded ingredient based on one of Eevia's extracts.

These investigations included analytical work and safety studies (toxicology studies), which have provided evidence that the ingredient is safe. The Parties are set to enter into a new phase of collaboration to support the launch of a rebranded product. The potential partner is a science-oriented global market leader.

Eevia has successfully produced multiple industrial-scale batches of the product and provides technical and scientific support to the international partner. With safety studies now completed, the plan is to initiate human clinical research and do a full market launch when the clinical study is completed. In May 2025, partner will pre-launch a rebranded product in some territories of the global nutraceutical market.